10 Stocks Posting Monster Gains Amid Market Downfall

Wall Street fell sharply on Thursday, as investors continued to unload positions amid lingering concerns about the artificial intelligence buildout, while repositioning portfolios ahead of the Federal Reserve’s December meeting.

Against this backdrop, 10 stocks boasted gains, thanks to a flurry of strong earnings. In this article, we identify their names and detail the reasons behind their gains.

To come up with the list, we considered the stocks with more than $1 billion in market capitalization and 5 million shares in trading volume.

The New York Stock Exchange building. Photo by Дмитрий Трепольский on Pexels

10. Palo Alto Networks Inc. (NASDAW:PANW)

Palo Alto climbed for a second day on Thursday, adding 6.42 percent to close at $361.73 apiece following solid earnings and a higher growth outlook, further supported by plans to expand beyond security services.

In its earnings call on Wednesday, the cybersecurity giant said that it grew its net income by 44 percent to $482 million from $334 million in the same period last year.

Total revenues exceeded company expectations, jumping 39 percent to $3.44 billion from $2.47 billion year-on-year amid the strong demand for security services from customers seeking further protection against cyber threats.

Given the current threat environment, Palo Alto Networks Inc. (NASDAW:PANW) CFO Dipak Golechha said that the company has raised its growth outlook for the fiscal year, with total revenues now expected to grow by 26 to 27 percent, to a range of $14.52 billion to $14.57 billion, versus the 23 to 24 percent projected previously.

NGS-ARR is also now targeted at $11.475 billion to $11.525 billion, representing year-over-year growth of 26 percent to 27 percent, versus 22 to 23 percent earlier.

For the second quarter alone, total revenues are expected at $3.53 billion to $3.55 billion, or an implied growth of 36 to 37 percent.

NGS-ARR is targeted at $10.20 billion to $10.22 billion, or an implied 61 percent year-on-year jump.

Separately, Palo Alto Networks Inc. (NASDAW:PANW) announced plans to acquire Applied Compute in an all-stock transaction valued at $4.5 billion, as it seeks to expand beyond cybersecurity and help businesses securely train, customize, and deploy open-source and open-weight AI models.

9. Full Truck Alliance Co. Ltd. (NYSE:YMM)

Full Truck Alliance rallied for a second day on Thursday, climbing 8.11 percent to close at $9.06 after posting a strong earnings performance in the third quarter of the year, despite the threats of surging oil prices on the shipping industry during the period.

In an updated report, the China-based digital freight platform said that its net income attributable to shareholders jumped by 50 percent to 1.36 billion yuan from 907 million yuan in the same period last year. Total net revenues grew 6.8 percent to 3.586 billion yuan from 3.358 billion yuan year-on-year.

Full Truck Alliance Co. Ltd. (NYSE:YMM) President Langbo Guo underscored the company’s strong transaction revenues during the period, having grown 25 percent year-on-year to 1.82 billion yuan.

Looking ahead, Full Truck Alliance Co. Ltd. is planning to expand its AI adoption through integrating AI agents into capacity dispatching across a wider range of routes to improve fulfillment efficiency.

For the fourth quarter of the year, the company is targeting total net revenues between 3.19 billion yuan to 3.29 billion yuan, representing a flat growth of at least 3.1 percent year-on-year.

In line with the results, its board of directors approved the distribution of cash dividends amounting to $0.0042 per ordinary share, or $0.0840 per American depositary share, to all shareholders as of the January 7, 2027 record. The dividends are payable on January 21.

8. Savara Inc. (NASDAQ:SVRA)

Savara extended its winning streak to a third consecutive day on Thursday, surging 10.38 percent to close at $5.21 apiece, as investors began positioning portfolios ahead of the Food and Drug Administration’s (FDA) decision on its treatment candidate for autoimmune pulmonary alveolar proteinosis (PAP).

The FDA is expected to announce its decision on Savara Inc.’s (NASDAQ:SVRA) biologics license application for Molbreevi on Sunday, November 22.

Earlier this year, the company said that it is focusing on the potential launch of Molbreevi in the US, representing its nearest-term opportunity, supported by a strong balance sheet to ensure commercial readiness. It is also awaiting decisions from regulators in Europe and the UK.

Molbreevi holds the potential to tap more than $2 billion in total addressable market in the US alone, with an estimated 5,500 patients and pricing power of $400,000 to $500,000 per year, as the treatment targets a rare disease with limited therapeutic alternatives.

Molbreevi aside, Savara Inc. holds a strong buy rating from eight analysts covering the stock, the most recent being HC Wainwright and Oppenheimer, reiterating their buy calls with price targets of $10 and $11, respectively. The figures marked upsides of 91.94 percent and 111.13 percent from its latest closing price, signaling a highly optimistic outlook for the stock.

7. Valvoline Inc. (NYSE:VVV)

Valvoline grew its share prices by 10.40 percent on Thursday to close at $36.84 each, with investor sentiment bolstered by its highly optimistic outlook for its business, supported by strong revenues in the fourth quarter of fiscal year 2026.

In an earnings call during the day, the preventive automotive maintenance giant said that it grew its net revenues for the fourth quarter ending September by 22 percent to $554.1 million from $453.8 million in the same period last year. System-wide store sales increased 20 percent to $1.1 billion.

Additionally, investors cheered Valvoline Inc.’s (NYSE:VVV) optimism for its business, having aggressively expanded its stores by 2,517 in the full fiscal year. The company added 61 stores in the fourth quarter alone.

For fiscal year 2027, the company is targeting net revenues between $2.25 billion and $2.35 billion, or an implied growth of 7 percent to 12 percent year-on-year.

Adjusted EBITDA is projected at $595 million to $625 million, or growth of 7 percent to 12 percent versus last year.

“Looking ahead to fiscal 2027, we expect another year of strong growth,” Valvoline Inc. President and CEO Lori Flees said.

“Our outlook assumes no change in the supply environment—stable availability and continued elevated product costs. Our team will keep executing with discipline, staying focused on serving our customers, growing our network and managing costs. We remain confident in the underlying strength of our business and the long-term value we can create for shareholders,” she added.

6. BellRing Brands Inc. (NYSE:BRBR)

BellRing Brands extended its winning streak to a third consecutive day on Thursday, surging 10.61 percent to end at $15.11 apiece, as investor sentiment was bolstered by higher price targets from six investment firms following its earnings performance in the fourth quarter of fiscal year 2026.

Among the six, Stifel Nicolaus and JP Morgan became the most bullish, reiterating their buy calls and raising their price targets to $18 from $15. DA Davidson also raised its price target for the stock to $17 from $15, while reiterating its buy recommendation.

Meanwhile, UBS, TD Cowen, and Bernstein also raised their price targets to $15 from $9.50, $9, and $13, respectively, but only advised investors to hold.

The coverage followed BellRing Brands Inc.’s (NYSE:BRBR) strong revenue performance in the fourth quarter, with net sales jumping 6.7 percent to $$692 million from $648.2 million in the same period last year, driven by a 14.9 percent increase in volume and an 8.1 percent decrease in price/mix.

Net earnings, on the other hand, fell by 40.27 percent to $35.6 million from $59.6 million year-on-year, dragged down by significant input cost inflation (inclusive of tariffs), incremental trade investment, and higher freight.

Looking ahead, BellRing Brands is targeting net sales between $2.32 billion and $2.42 billion, or an implied decline of 3 percent or flat year-on-year.

In a separate development, BellRing Brands named Travis Leonard as its new chief finance officer effective December 1, 2026, replacing Paul Rode, who will serve in an advisory capacity through February 28, 2027.

Leonard brings more than 25 years of financial leadership experience, including prior service as CFO in the consumer products industry.

5. PDD Holdings Inc. (NASDAQ:PDD)

PDD Holdings saw its share price jump by 11.04 percent on Thursday to end at $86 apiece, after beating earnings expectations in the third quarter of the year.

In an earnings release, the Temu operator said that adjusted net profit ended at 31 billion yuan, exceeding the 28.03 billion as analysts expected.

Revenues, however, fell short of estimates, closing at 108.3 billion yuan versus the 115.97 billion yuan as Wall Street expected. The figure was also flat from the same comparable period.

Meanwhile, total operating expenses decreased by 12 percent to 31.9 billion yuan from 36.4 billion yuan year-on-year, primarily due to 16.5 percent lower sales and marketing expenses.

General and administrative expenses also declined by 11 percent to 1.6 billion yuan from 1.8 billion.

Only research and development costs grew by 18.6 percent to 5.1 billion yuan versus 4.3 billion yuan year-on-year.

PDD Holdings Inc. (NASDAQ:PDD) acknowledged the evolving global trade and regulatory environment, but noted that it remains committed to deepening its supply chain investments.

“We see significant potential to build on this progress and will continue investing in the tools and services that help our merchants grow,” said PDD Holdings Inc. co-Chairman and co-CEO Lei Chen.

4. Telus Corp. (NYSE:TU)

Telus Corp. saw its share price jump by 13.35 percent on Thursday to finish at $10.78 apiece, as investors resumed buying positions on expectations of a higher takeover offer amid a brewing bidding war between two Canadian telco giants.

This followed a comment from one of the bidders, Quebecor, on Thursday, slamming Telus Corp.’s (NYSE:TU) potential merger with its competitor, BCE Inc. or Bell Canada.

Quebecor said that while interest being shown by Bell Canada’s parent company in acquiring Telus Corp. would strengthen a three-player telecom market, their potential would not represent a positive outcome for consumers.

It can be recalled that Quebecor offered to take over Telus in June 2026, while the latter also held preliminary talks with Bell Canada for a potential merger.

In a statement earlier in the week, Telus Corp. said that it continues to explore other strategic alternatives after raising concerns and identifying risks associated with Quebecor’s proposal.

“With respect to the financial terms, the Board is not satisfied that the consideration offered under the proposal adequately reflects the value of Telus, its leading position in the Canadian telecommunications market, nor the value creation opportunities available to Telus through continued execution of Telus’ strategic plan,” the listed firm said.

3. Opendoor Technologies Inc. (NASDAQ:OPEN)

Opendoor Technologies grew its share price by 14.96 percent on Thursday to end at $1.46 apiece as investors loaded portfolios ahead of tomorrow’s expiration of three warrant series.

In a regulatory filing on the same day, Opendoor Technologies Inc. (NASDAQ:OPEN) said that its Series K, A, and Z warrants are nearing expiration without extension.

The upcoming warrant delisting could offer some relief to existing investors as it removes a potential source of future share dilution, with the company no longer obligated to issue additional shares.

Warrants aside, Opendoor Technologies Inc. earlier this year reported strong revenues in the third quarter of the year at $1.022 billion, or a 12 percent jump from the $915 million in the same period last year.

Net loss, however, widened by 142 percent to $218 million from $90 million year-on-year.

For the fourth quarter of the year, Opendoor Technologies Inc. is targeting revenues to grow at least 40 percent year-on-year, while adjusted EBITDA is targeted at a loss of $70 million to $85 million.

“We are driving to Adjusted Net Income positive by the end of 2026, measured on a twelve-month go-forward basis. We are currently behind, but we intend to catch up,” it said.

2. Anthropic PBC (NASDAQ:ANT)

AI startup Anthropic PBC made a blockbuster debut on the US stock market on Thursday, with its shares skyrocketing by 17.07 percent to close at $97.17 apiece, in what is now considered the largest initial public offering (IPO) in history, marking a new milestone for the artificial intelligence industry.

The Claude creator—which trades under the ticker symbol “ANT”—immediately opened 34 percent higher than its IPO price of $83, jumped by as much as 39 percent to hit $115.10, before paring gains toward the close. It was able to raise $81.3 billion in fresh funds following the successful sale of 980 million shares.

Anthropic PBC (NASDAQ:ANT) closed the day with an estimated fully diluted valuation of approximately $1.28 trillion, retreating from the $2 trillion valuation implied by its opening price.

The strong uptake signaled renewed investor confidence for the AI sector, which has been reeling from a series of setbacks, including higher interest rates, further dragged down by Jensen Huang’s resignation as chief executive officer of Nvidia Corp.

Several technology giants hold significant exposure to Anthropic, including Amazon and Google, which both own stakes of up to $100 billion.

Other firms, namely Microsoft, Nvidia, and Advanced Micro Devices also collectively own $26 billion in the firm.

1. Insmed Inc. (NASDAQ:INSM)

Shares of Insmed Inc. soared 20.58 percent on Thursday to close at $144.46 apiece following reports that French pharmaceutical firm Sanofi SA is planning to acquire the company in what could be the largest transaction so far in the biopharmaceutical industry.

A report by Bloomberg earlier in the day, citing people privy to the matter, said that Sanofi is currently in talks with its investment advisors to evaluate the potential transaction. The transaction is not yet guaranteed, with a decision potentially weeks away.

Neither party confirmed nor denied the report, but ADRs of Sanofi SA dropped by 2.25 percent during the day.

The report followed the appointment of former Sanofi SA Chief Executive Officer Paul Hudson as one of the newest independent members of its board of directors last month, alongside Utpal Koppikar, Finance chief of Verily Health.

The planned acquisition aligns with Sanofi SA’s efforts to expand its presence in the respiratory market, particularly through Insmed Inc.’s (NASDAQ: INSM) Brinsupri, an FDA-approved treatment for non-cystic fibrosis bronchiectasis, and Arikayce, an inhaled antibiotic for MAC lung disease.

In the third quarter of the year, Brinsupri alone accounted for $400.1 million of Insmed Inc.’s total revenues, propelling a jump of 1,324 percent from only $28.1 million registered in the same period last year.

Arikayce accounted for $124.4 million, or a jump of 9 percent from $114.3 million year-on-year.

READ NEXT: Billionaire Stanley Druckenmiller’s New AI Warning and Top 10 Stock Picks

Disclosure: None. Follow Insider Monkey on Google News.